N,N-Dipropyltryptamine

The following information was compiled in October 2025 and is subject to change as new research is conducted and as new information becomes available:

Description: N,N-Dipropyltryptamine (DPT) is a synthetic hallucinogen categorized as a tryptamine analogue. DPT is structurally similar to other tryptamine analogues (e.g., dimethyltryptamine, diethyltryptamine, diisopropyltryptamine). DPT was initially synthesized in the 1960s for use as supplementary treatment for psychotherapy.¹ DPT was first identified by our laboratory in March 2025 and confirmed after acquiring standard reference material.

Sample Source: Chicago Recovery Alliance (Chicago, IL)

Sample Appearance: White solid material

Pharmacology: N,N-Dipropyltryptamine (DPT) is reported to be an agonist at the 5-HT_2A receptor and inhibits monoamine reuptake with little effects on monoamine release. DPT is also reported to produce similar hallucinogenic effects to LSD, psilocybin, and MDMA.^1,2

Toxicology: N,N-Dipropyltryptamine has not been detected in toxicology cases to date at the CFSRE.

Drug Materials: N,N-Dipropyltryptamine has been detected in one drug material to date at the CFSRE.

Demographics / Geographics: The drug material originated from Illinois.

Legal Status: N,N-Dipropyltryptamine (DPT) is not currently scheduled in the United States.

Class:

Hallucinogen

Appearance:

White solid material

Formula:

C16H24N2

MW:

244.4

[M+]:

244

[M+H]+:

245.2012

IUPAC:

N-[2-(1H-indol-3-yl)ethyl]-N-propyl-propan-1-amine

Report Date:

October 3, 2025